Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Asep Medical Holdings Inc. (OTCQB: SEPSF) announced a joint venture with Sansure Biotech Inc. on January 27, 2023, aimed at commercializing the SepsetER sepsis diagnostic kit in China. The agreement, signed on September 29, 2022, outlines collaboration terms for research, development, and sublicensing in the Chinese market. Sansure will invest capital and Asep will receive royalties on sales. With a high sepsis mortality rate in China, this partnership is positioned to offer advanced diagnostic solutions, enhancing early detection capabilities while potentially reducing antibiotic resistance.
Asep Medical Holdings Inc. (CSE: ASEP, OTCQB: SEPSF) announced an online webinar on January 24, 2023, at 1:00 pm EST, to discuss global market developments, scientific advances, and investment milestones. Key topics include updates on the acquisition of SafeCoat Medical Inc., a joint venture with Bahrain's Seaspring W.L.L., and advancements in their sepsis diagnostic test kit, SepsetME. The webinar will also cover a feasibility study for an antibacterial mouthwash in China and the development of new wound bandages. The company aims to address significant medical needs associated with antibiotic failure.